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1 Executive Summary
Muscle spasticity is a common and debilitating complaint among patients with cerebral palsy, multiple sclerosis, or
spinal cord injury (Albright et al. (1991)). A drug called Baclofen has been developed that functions by affecting
certain GABA neurotransmitter receptors in the spine. This problem has been partially addressed by modern treatment
methods. One of these methods is one through which drugs are pumped directly into the intrathecal space of the spine
rather than being administered systemically. However, since slight changes in drug concentrations in the intrathecal
space may have much more severe consequences to a patient, the delivery of Baclofen must be subject to stricter
control over pump input and flow parameters. A safe range of input concentrations and flow rates must be proposed.
This will result in a safer method of optimizing these parameters so that the reliance on potentially lethal clinical trials
ceases.
To address these requirements, a computational domain was created, modeled as two concentric cylinders (purely
containing cerebrospinal fluid and the other containing the grey and white matter), and restricted to the lumbar region
of the spine. The results of these experiments address the need for a safe and effective range of concentrations and
flow rates for pump-driven delivery of Baclofen. The input concentration of Baclofen was 500 g/m3 and the input
pump velocity was 2 m/s. The COMSOL simulation demonstrated a saturation the vertebral column with the drug
spread confined to a 30 mm distance from the injection site. We determined an optimal concentration of 250 g/m3
at a pump velocity of 10 m/s. The model was insensitive to changes in diffusion and changes in pressure boundary
conditions. Note that ultimately, the choices for injection flow rate and injection concentration were produced only for
a 1 minute duration of treatment. This portrayed a computational model of a single bolus injection of Baclofen rather
than a continuous drug pump. With more resources to run the model for a longer time duration, a more accurate model
can be achieved.
These results should be tested experimentally before being put to widespread use. However, it is likely that they
can be used to direct the placement of a Baclofen pump and the concentration and flow rate of Baclofen through
that pump. Using these results, doctors will be able to minimize adverse drug effects while simultaneously providing
adequate concentrations of Baclofen to the target areas. This computational method of optimizing input concentration
and flow rates in the intrathecal space can be expanded to attain these parameters for other drugs.
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2 Introduction
2.1 Background
Muscle spasticity is a condition where a patient exhibits a progressively increasing pathologic muscle tonus until
voluntary movement of the affected limb(s) is severely limited. This condition affects two-thirds of patients, primarily
children, with cerebral palsy (Albright et al. (1991)). Similarly, patients with certain forms of spinal cord injury or
multiple sclerosis and those who often exhibit symptoms with a similar pathophysiology to that of cerebral palsy,
experience chronic spasticity that drastically degrades their standard of living. Baclofen, a synthetic derivative of the
neurotransmitter gamma-Aminobutyric acid (GABA), was first synthesized by Heinreich Keberle in 1962 (Watve et al.
(2011)). It has become the leading therapeutic drug in the management of chronic spasticity.
Baclofen affects GABA receptors at the spinal level and reduces propagation of action potentials along alpha
motor neurons. In other words, it behaves as a potent, targeted muscle relaxant. Keberle designed the drug for oral
administration. Due to the molecules similarity to GABA (Watve et al. (2011)), he increased its lipophilicity to improve
the molecules ability to penetrate the blood-brain barrier into the cerebrospinal fluid (CSF) above the dorsal nerve roots
supplying the affected muscles (Blackburn (2010)). As an orally dosed medication, Baclofen was a partial success.
The drug could reach clinically effective concentrations in the CSF, but not without introducing a host of debilitating
over-dose effects due to its systemic delivery route. Patients complained of hypotension, bradycardia/tachycardia,
flaccid paralysis, among other symptoms (Haranhalli et al. (2011)).
In clinical trials by Richard D. Penn and his colleagues, the drug was administered directly to the target region,
the CSF proximal to the affected dorsal roots. The patients in the studies were experiencing spasticity so severe that
surgeons considered completely transecting the nerve roots. After the treatment, they were able to walk again after
19 years of pain. A delivery pump was devised to administer low doses of baclofen directly into the CSF-filled sub-
arachnoid space, or intrathecal space, of the spine (Haranhalli et al. (2011)) (Penn (1988)). Earlier, the treatment
involved 100 mg bolus oral dose of baclofen to achieve a concentration of <3 ng/g in the targetted locale in the CSF,
a 600 ug dose could achieve local concentrations of 5-20 ng/g (Haranhalli et al. (2011)). Penn proposed a course of
treatment where fluid from a reservoir could be pumped 5 muL/hr to deliever 25-50 ug doses within a course of 8-12
hours (Penn (1988)).
The current generation of intrathecal delivery pumps, such as the Medtronic Intrathecal Baclofen Treatment pumps
shown in Figure 1, treat not only muscle spasticity but also chronic conditions such as nonmalignant pain (Het-
tiarachchi et al. (2011)). They administer low doses of opioids to limit the effects of tolerance. These devices use a
silicone catheter, inserted posteriorly to target the arachnoid membrane, and a battery-driven pump that draws fluid
from a sub-dermal reservoir (Coffey et al. (2002)). The devices come with several different tunable settings for pump
flow.
Figure 1: A representation of the intrathecal delivery pump in the spinal canal. An illustration from Medtronic detailing
the use of the Baclofen pump on an individual with severe muscle tonus or pain. The needle is inserted directly into
the spinal cord to directly provide pain relief at the source.
Devices, such as the one in Figure 1, have existed to treat chonic conditions such as muscle spasticity or nonma-
lignant pain (Hettiarachchi et al. (2011)). These devices use a catheter, inserted posterior to target the space under the
arachnoid membrane of the spinal cord. Spasticity management, an uneasy balance between alleviating unmanageable
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pathological tonus and moderating collateral damage to organs serving as intermediate checkpoints in the delivery
route, often involves the injection drugs such as Baclofen; however, localization of the drug in the desired target locus
along the spinal canal requires pre-modeling of the pump insertion site and flow rates (Hettiarachchi et al. (2011)).Tak-
ing into account the natural periodic flow of cerebrospinal fluid in the spinal canal (Sweetman and Linninger (2011)),
surgical considerations for the catheter insertion approach, and the device’s flow settings, we expect to suggest device
flow rates and insertion sites to restrict drug delivery so that the minimal effective concentration is attained only in the
affected region of the spine, restricted in both vertical and cross-sectional directions.
Despite these devices providing fine control over delivery of Baclofen, spasticity management remains an uneasy
balance between alleviating unmanageable patholgical tonus and moderating collateral damage and over dose. The
trade-off inherent in directly accessing the intrathecal space is that any minor miscalculation in dosing has several
orders of magnitude higher affect than a similar miscalculation in oral dosing. In our study, we expect to anticipate
these problems by varying pump flow and concentration parameters and examining simulated concentration profiles
that take into account the natural periodic flow of the CSF in the spinal canal (Sweetman and Linninger (2011)),
surgical considerations for the insertion of the catheters.
2.2 Design Objectives
The first objective is to demonstrate the efficacy of the model to predict accurate outcomes given the standard treat-
ment procedure. The second objective is to determine optimal injection concentrations and flow settings to minimize
overdose and maximize drug functions.
This project aims to select and specify a safe pump concentration of Baclofen and an injection velocity by com-
paring maximum concentrations in the L1 - L3 region, which is located in the mid to lower torso of the spinal chord
to ensure they lie within the minimal effective concentration range. Further investigation will be done to ensure that
this method of delivery is practical and safe for patients patients with spastic pain.
Numerical and analytic methods were used to model the spinal cord while also considering drug concentration
gradients that occur vertically and laterally along the canal. In doing so, the curvature of the spine, the widths of
vertebra, the direction and speed of cerebrospinal fluid flow, and the natural diffusive properties of Baclofen must be
considered. After injection, the drug will not just follow a simple diffusion problem. It will also have a convective
component as prescribed by a sinusoidal approximation of the periodic flow of CSF in the intrathecal space (Sweetman
and Linninger (2011)), which characterizes our top and bottom boundary conditions.
3 Problem Formulation
3.1 Schematic
From the current intrathecal delivery pumps (Hettiarachchi et al. (2011)), an anatomically correct schematic of the
spinal cord is shown in Figure 2.
Figure 2: A 3-D Representation of the anatomy of the spine and how the Medtronic Baclofen pump would be surgically
placed in a patient. This diagram portrays the spatial layout of the spinal chord, intrathecal space, and the catheter
needle with respect to each other.
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3.2 Assumptions
The model focuses on investigating a portion of the lumbar region of the spine, specifically the L1-L3 vertebrae. The
model is restricted to regions of relatively constant diameters without the tapered ends of the sacrum. The solid core
diameter is also approximated to be the size of intrathecal space subtracted from diameter of spinal canal (this is overly
emphasized in the schematic in Figures 2 and 3).
An idealized cylindrical model (Figure 3) of the intrathecal space provides a more practical computational domain
for actual drug transport than a model that expands the computational domain to include the bony structure of the
vertebral column in which the space is sequestered (Figure 2). As drug distribution is most rapid through fluids, the
distribution of the drug will most likely be influenced by the regions containing cerebrospinal fluid (CSF).
The flow of the CSF, a function of the cardiac cycle due to its close connection to the systemic flow of blood,
contributes an additional complexity to the model of the distribution of Baclofen. Studies have argued that this flow
has a nontrivial impact on the distribution of a drug from the injection site along the spinal canal (Sweetman and
Linninger (2011)). The flow of CSF has been experimentally designed between the L1 and L3 vertebrae of the spine,
between which catheters pump spine-targeting drugs in clinical trials of intrathecal delivery systems.
3.3 Model Development
In COMSOL, a computational domain, modeled as two concentric cylinders (one purely containing CSF and the other
containing the dorsal nerve roots) was created (Figure 3). This model was restricted to the lumbar region of the
spine. The concentration of Baclofen was calculated using the mass species general equation. The injection needle is
modeled with the Navier Stokes equations to determine the velocity of the drug flowing into the CSF. The flow of CSF
is calculated using Darcy’s Law. This design takes into account the natural periodic flow of the cerebral spinal fluid
(CSF). This flow characterizes our top and bottom boundary conditions, and was approximated as a periodic function
(with a single period being that of the cardiac cycle)(Sweetman and Linninger (2011)).
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3.3.1 Governing Equations
The geometry that was implemented in COMSOL consists of a simplification of the scenario seen in vivo, as shown
in Figure 2. Figure 3 shows all of the subdomains and the governing equations important in the implementation of
the model.
Figure 3: The schematic of the 3D model, as used in COMSOL and in relation to Figure 2, with the governing
equations: (1) Mass Species General Equation is implemented in all three subdomains, (2) Darcy’s Law is implemented
in the subdomains of the spinal chord, and (3) The Navier-Stokes Equations are implemented in the injection needle
Figure 3 is modeled after Figure 2, and it shows the parameters of the COMSOL geometry. The governing
equations that were used in COMSOL are also included. The dimensions chosen for the geometry in COMSOL were
taken from typical values determined by previous studies in the literature (Gilad and Nissan (1985), Gra (1919)).
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3.3.2 Boundary and Initial Conditions
Each governing equation requires separate boundary conditions. The mass species general equation is implemented
so that there is no flux of Baclofen at the epidural boundary layer. At the solid core there is a continuity condition so
that the amount of Baclofen being transported is preserved within the model. At the top and bottom portions of the
spinal cord, there is convective flux due to the pressure flow of the CSF (Table 1). Figure 4 shows the schematic with
the mass species boundary conditions.
Figure 4: The 3D COMSOL model with the Mass Species General Equation’s Boundary Conditions. The specific
boundary conditions can be referenced in Table 1.
The initial condition is that there is there is a 500 g/m3 injection of Baclofen at the injection needle. However, the
concentration of Baclofen elsewhere in the system is zero (Table 1). The boundary at the injection site is modeled with
a constant concentration boundary because it is most reasonable given that the Baclofen reservoir can be simplified as
an infinite source for the drug.
Darcy’s Law calculates the flow of CSF due to a pressure difference profile between the top and bottom of the
schematic’s geometry. This data was calculated from Sweetman and Linninger (2011).
In Figure 5, the pressure boundary conditions at the top and bottom of the schematic are shown. The injection
velocity is specified at 2 m/s at the injection needle. Meanwhile, there is an insulated boundary condition at the
epidural layer, and there is a continuity boundary condition at the solid core boundary (Table 1).
Figure 5: The 3D COMSOL model with the Darcy’s Law Boundary Conditions. The specific boundary conditions can
be referenced in Table 1.
These pressure profiles closely match the natural flow of CSF in the body (Table 1).These profiles were determined
by data from Sweetman and Linninger (2011). The data was taken and transformed into the frequency domain by the
Fourier transform. The largest components of this transform were taken as simplified functions for the top and bottom
boundary conditions.
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3.3.3 Limitations
The main limitations of this model are the simplifications made from deviating from the anatomy of this problem. The
oversimplification of the CSF flow profile may affect the distribution of Baclofen in this study. The original spinal
chord processes that affect the canal and the intrathecal space. Another limitation is that the injection needle, in the
COMSOL geometry, is perpendicularly placed to the vertical axis of the spinal chord.
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4 Results
Following simplifications of the computational model to accommodate difficulties encountered with computational
time and memory allocation (namely a shortened run time and a coarser mesh than recommended through mesh
convergence analysis), COMSOL returned a solution for the concentration distribution of Baclofen, shown in Figure
6, given an initial injection concentration of 500 g/m3 and an initial pump velocity of 2 m/s.
Figure 6: Distribution of Baclofen along the Surface of the Spinal Cord in intervals of 10 seconds for a duration of 60
seconds.
Interestingly, the concentration profile, in Figure 6, indicates rapid saturation of the spinal column within the 60
second run-time that resembled an injection of a single, large bolus of baclofen. While a clear departure from the
desired chronic treatment protocol, whereby the concentration of Baclofen in the intrathecal space would level off in
a much longer time-scale (out to days), the concentration profile demonstrates that the 500 g/m3 doses utilized by
Medtronic SynchroMed pumps (Saval and Chiado (2008)) will bring the average concentration of the 10 cm column
of interest to the pump concentration within minutes of treatment.
In Figure 7, the concentration profile depicts the spread of the drug along two curved advancing fronts, headed
towards the top and the bottom of the two cylinder model. Within these fronts, which traveled along the length of the
2-cylinder model at a velocity of approximately 4 mm/s, the entire intrathecal space and spinal cord was saturated
with Baclofen.
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Figure 7: The concentration profile throughout the 60 second duration. Part (a) demonstrates the spread of the drug
from the spinal column view at 1 second, 30 seconds, and 60 seconds. Note that at 1 second, the spread of the drug
is witin 15 mm from the injection needle while at 60 seconds, the spread of the drug has increased to being within
60 mm from the injection needle. Part (b) demonstrates a top view of the cross section of the spinal column at 60
seconds.
As shown in Figure 7, the drugs spread was confined to a region within 15 mm from the injection site after
simulation of one second of treatment. At the end of the 60-s runtime, the spread was confined to a region a little
more than 30 mm from the injection site. A cross-section of the spinal column shown in Figure 7, taken at the top of
the region of interest in order to view concentration distribution in unsaturated regions of the spine, indicates that the
concentration fronts are largely localized in the solid core before saturating outlying regions in the intrathecal space.
This, again, points to rapid therapeutic potential of a single bolus treatment and suggests possible drawbacks to the
treatment scheme, as the distribution of Baclofen implies that the solid core bears the brunt of the Baclofen saturation
and the most crucial(and easily damaged) tissue of the spinal canal could be easily impacted when over dosing.
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5 Discussion
5.1 Optimization
The injection flow rate and injection concentration are optimized by doing an optimization of the Baclofen concentra-
tion both in the target area and in the rest of the spine. To solve this optimization problem, the target area concentration
is calculated with a variety of injection flow rates and injection concentrations, and the best of each is chosen. The best
result was determined by an equation that rewarded concentrations within the accepted range in the target region and
rewarded low concentrations anywhere else. This was to minimize the adverse affects but maintain functionality. To
determine the ideal location of the injection, this is done with the injection point in between several different vertebrae,
and the best one is chosen.
Ideally, Baclofen should be delivered at efficient, sub-lethal concentrations directly on the dorsal nerve root core of
the computational domain, and remain well below lethal concentrations throughout the entire spinal canal (i.e. the en-
tire computational domain). Assuming minimum efficacy of a drug to be about 250 g/m3, a concentration comparable
to one that can be achieved through oral or systemic delivery of Baclofen (Penn 1988), and an overdose concentra-
tion of greater than 450 g/m3, a set of objective functions could be attained to optimize the input concentrations of
Baclofen delivered through the aperture of the computational domain:
ΣFT = ΣFwithininnercylinder + ΣFwithinoutercylinder
ΣFwithininnercylinder =
{
(250 gm3ofCSF − c) ∗ 2, if c < 250 gm3ofCSF
(c− 450 gm3ofCSF ) ∗ 3, if c > 450 gm3ofCSF
ΣFwithinoutercylinder =
{
(c− 450 gm3ofCSF ) ∗ 1, if c > 450 gm3ofCSF
Starting from a concentration of Baclofen delivered clinically in market standard intrathecal devices, a range of
lower input concentrations at varying inlet velocities were tested to determine optimum input concentration setting for
delivery in a one minute treatment session in Figure 8.
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Figure 8: Values of the Optimization of the Concentration of Baclofen
In Figure 8, with the data that was run in COMSOL using the objective functions, it is determined that more
concentration/inlet velocity trials must be done. This was not done due to lack of computational time. In Figure Figure
8, concentrations only one inlet velocity (5 m/s) were run. Independent parametric sweeps were not performed for
velocities at each concentration. However, a velocity and an injection concentration were paired to attain a rough
estimate of an ideal pump setting. Therefore, the optimal concentration for these trials is the lowest point on Figure
8: 250 g/m3 at 10 m/s.
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5.2 Sensitivity Analysis
While the focus of this study was assessing the optimal injection concentration of Baclofen and inlet velocity from the
pump of the device, the sensitivity of the model to these input values should also be compared against the sensitivity
to additional properties and parameters defining the function of the device. The sensitivity analysis done in this study
is shown in Figure 9.
Figure 9: Sensitivity analysis was performed using a range of values for the amplitudes of the sinusoidal pressure pro-
file defining the top and bottom conditions of the graph, the inlet velocity from the pump, the injection concentration,
and the diffusivity of baclofen. Graphs indicate little variation in the concentration of baclofen in the solid core with
variation with changing boundary conditions and diffusivity after a 60 second run time. Altering inlet velocity and
concentration, however, caused significant changes to the concentration distributed in the solid core. (Concentration
changes are indicated in upper row; O.P. indicates original parameter value)
For instance, one of the considerations being addressed in this study is the impact of cerebrospinal fluid flow within
the spinal column on the distribution of the drug. One hypothesis was that the drug would reach a farther spread within
the computational domain defined in this study; however, COMSOL solutions performed with 60-s run-times did not
support this conjecture. Adjusting the amplitude of the sinusoidal functions defining the top and bottom boundary
conditions altered the average concentration within the inner solid core of the spine by less than 0.04% even with
order of magnitude variations. One possible rationale for this result was that fluctuating CSF pressure profiles would
only play a strong role in drug distribution if diffusion played a significant role in the distribution of the drug from a
pump-operated system.
The sensitivity analysis for diffusivity revealed that diffusivity did little to alter the concentration of baclofen in the
solid core, with just a little more than 0.05% alteration when the diffusivity was considered one order of magnitude
less than that of Baclofen in CSF. This suggests that this model can be generalized to other drugs.
As the model was sensitive to inlet velocity of the pump, with about 40% reductions in concentration when the
velocity was halved, the COMSOL solutions suggest that convection predominates as the major component in the
drug delivery system. Interestingly, increasing the inlet velocity did not alter the concentrations within the column,
suggesting that the velocity used in a majority of the simulations (2 m/s) already caused saturation of the solid
core. As expected, the solid core concentration varied most in response to increases in the injection concentration
of the device, with the core concentration values almost scaling exactly with changes to the injection concentration,
justifying the choice to optimize the injection concentration in this study.
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5.3 Accuracy Check
Determining the accuracy of the model is an essential to creating a successful model. The best way to determine how
the model compares with real data would be to run a parallel experiment with all of the same input parameters and
conditions. This is the gold standard for determining the accuracy of a model and subsequently the legitimacy of its
claims.
As part of this investigation, experimental data parallel to the simulation had not been gathered but there have
been others who have performed similar experiments. The experiments Hettiarachchi et al had performed were highly
similar to the ones that we are trying to model. In their experiments, they injected substances, such as flourescent dye
that has a similar molecular weight to Baclofen, into a mechanical set up acting as a human spinal cord surrogate.
When the results from this experiment, Figure 10a, and the experiments from literature, Figure 10b, are compared
side by side, they are seen to be highly similar.
Figure 10: Side by side comparison of the displacement of Baclofen over time. Part (a) shows the results from this
study. Part (b) shows a flourescent dye experiment done by Hettiarachchi et al. (2011).
It is important to note that, though the data do not have the exact corresponding time duration, the time that does
apply to this model (time under 1 minute) does correspond nicely with the experiment shown here in the stagnant case.
It is reasonable to compare our model to the stagnant case since we are modeling only the very lower section of the
spinal cord. This section has the lowest rates of flow inside the spinal cord and hence flow rates would not be as high
compared to in their experiment.
The striking discrepancy between the experimental setup and the set up of this simulation is the drug/molecule for
injection. In the case of our model we had used Baclofen, a typical pain relieving drug, while in their experiments,
they had used fluorescent dye (Figure 10b). The properties of the molecular dye should be similar to Baclofen since
Hettiarachchi et al wanted to use the dye as a easily visualizable substitute for Baclofen in the experiment.
With the fluorescent dye experiment in Figure 10b, the value obtained at 1 minute is highly comparable to the
value in the simulation suggesting that the solution obtained from COMSOL is a reasonable one.
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6 Conclusion
6.1 Future Aims and Design Recommendations
Several significant simplifications were made to the original schematic of the intrathecal space and injection port to
decrease computational time and memory allocation requirements. These changes, however, may have rendered much
of this study nugatory, especially with respect to clinical applications of the intrathecal pump device. The catheter, for
instance, should not be inserted into the gray and white matter of the spinal cord under any circumstance. Doing so
will induce mechanical damage and possibly result in axotomy, or complete transection, of the nerves comprising the
cord. A redesign of the device schematic would, therefore, be benefitted by a different angle of entry for the catheter
and a much smaller needle gauge. This redesign will probably reflect a very different concentration distribution of
baclofen, as the drug will have to travel from the cerebrospinal fluid-only space into the porous solid core.
The solution times for each simulation in COMSOL, 1-3 minutes, also reflected a dramatic departure from funda-
mental aims driving this study. The current generations of Baclofen pump devices are intended to be worn chronically,
with a fully motile patient able to enjoy normal activities without worrying about drug dosing. This automation neces-
sitates a much larger time-scale of study. At the very least, the protocol defining Baclofen delivery should have been
tested out to a few days. Much slower injection velocities and smaller drug concentrations could have been used if the
device was designed to distribute an effective concentration of Baclofen temporally averaged over a day rather than
deliver a 1-3 minute single large bolus of the drug. At slower velocities, the effects of CSF flow may have been more
noticeable, as well.
Finally, the simplifications of the design necessitated the removal of important geometric factors and physiological
considerations regarding operations within the intrathecal space and spinal cord. The spinal column is often difficult
to access as entry must consider the discrete spacing of the vertebrae. Within the model used in this study, the site of
entry was assumed to be directly over the target location in the spinal cord. A more realistic model would suggest a set
number of discrete entry sites, with the optimization of the pump parameters focusing on arriving at an effective, safe
concentration at a more distally placed region of interest. Moreover, the problem formulation for the computational
simulation omitted the elimination component of the mass species equation. The drug must be metabolized to have
an effect in tissue. Of course, this might not be relevant in the 1-3 minute time-scale prescribed in the solutions of
the study; yet, at longer, clinically relevant time scales, drug metabolysis would actually be the main concern of the
model. Otherwise, the implication is that baclofen simply aggregates at the region of interest and no chronic dosing
would be necessary as the patient will always have the required amount of drug in his or her system.
To bring the model closer to physiological relevance, the exact geometry of the spinal canal could be rendered;
however, given the difficulties encountered in simulating complex CSF flow and drug transport in the simplified two
cylinder geometry of the model, this might be computationally impractical. At the very least, however, the study must
consider a clinically relevant time-span of treatment, a safe and physiologically possible placement of the catheter
in the spine, and the degradation and consumption of baclofen by the patient to be of any use to efforts directed at
improving chronic management of spasticity.
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6.2 Evaluation of the Design Objectives
In summary, the study was motivated by two major goals: characterizing the concentration distribution of the drug
Baclofen given a treatment protocol similar to that of the current generation of Intrathecal pumps (such as those by
Medtronic Inc) and identifying optimal injection concentration and pump flow settings to minimize risk of overdose
and maximize therapeutic function. As far as the first goal was concerned, the study was successful in demonstrating
the effects of treatment with the standard 500 g/m3 injection concentration setting, indicating that a zone of saturation
was established immediately after onset of treatment, with the spread of the drug nearly doubling over a one minute
period. The simplifications to the design and delivery method (constant injection), however, manufactured a protocol
that was more in line with what was expected of a single bolus injection, reducing the clinical relevance of the results.
Moreover, the effects of the internal CSF flow were demonstrated to be trivial at these rapid delivery settings. The
second goal was, therefore, only partially addressed, as ideal input concentration and velocities were determined (250
g/m3 at 10 m/s), but only for the simplified protocol and for a 1-minute treatment span. While this might dampen
the impact of the results from the study, especially with regards to chronic treatment of spasticity conditions, the
simulations, at the very least, demonstrated that a simulation of the drug treatment can provide an understanding of
the underlying importance of convection and diffusion on the transport of baclofen.
6.3 Realistic Constraints
6.3.1 Economic Constraints
While improved quality of life ought to be the primary concern for those suffering from spasticity conditions, the
unfortunate reality is that there are some very real financial constraints influencing patient care. The 5-year coust of
treatment with intrathecal baclofen therapy is about $ 49, 000 (De Lissovoy and Matza (2007)). While a good value
considering the surgical pricing and the cost of the drug involved in the therapy, the fact that the treatment manages
often non-lethal issues, the therapy might not be insured. This study was designed to consider lowering concentration
doses to provide safer, chronic treatment; however, creating a pump reservoir with a lower baclofen concentration
would imply that the pump reservoir must be refilled more frequently, which requires reopening the surgical site. This
would incur higher costs and may not be desired by doctors or patients attempting to manage the total cost of therapy.
6.3.2 Health and Social Constraints
While this study focused on a single-bolus approximation of pump delivery of baclofen, the focus was to attain an
optimal low dose, rapid delivery system in a chronic treatment plan. For minor spastic conditions, the use of a chronic
pump device poses several important constraints. The device, as modeled in this simulation, will still be fairly bulky,
with a subdermal battery pack causing issues regarding motility and flexibility to patients. The device is unlikely to
gain popularity among those suffering from minor spasticity conditions due to discomfort and possibly social aversion
to such an intrusive device. Moreover, invasive treatments, such as feeding tubes and intrathecal delivery systems,
are never considered socially responsible cosmetic options. This may limit the impetus to design more refined pump
therapies, as often the market driving management therapies is guided by cosmetic appeal of devices.
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7 Appendix A: Mathematical Statement of the Problem
7.1 Schematic
Figure 11: The 3D Schematic with labeled boundaries
7.2 The Mass Species Equation
THE MASS SPECIES EQUATION:
∂C
∂t
+ ~∇ · (~u (t)C) = ~∇ ·
(
D~∇C
)
(1)
7.3 The Darcy’s Law
THE DARCY’S LAW:
~q =
−k
µ
~∇P (2)
The experimental data attained by Sweetman and Linninger can be used to estimate pressure differences induced
within the computational domain in which the delivery of Baclofen is being modeled. The simulation will vary the
pressure difference induced across the top and bottom boundaries of the computational domain over the duration of
treatment, cycling through the pressure values every second (Table 1).
7.4 The Navier Stokes Equations
THE NAVIER–STOKES EQUATION:
∂u
∂t
+ (u · ∇)u = −1
ρ
∇p+ γ∇2u+ 1
ρ
F (3)
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7.5 The Boundary and Initial Conditions
Table 1: The Boundary and Initial Conditions for each General Equation with respect to Figure 11
Boundaries Mass Species Equation The Darcy’s Law Equation The Navier-Stoke’s Equation
Top
Boundary
Convective Flux Pressure:
−10(2 sin(40(x+ 20)
pi
)
−3 sin(20(x+ 20)
pi
+5)−56
N/A/
Bottom
Boundary
Convective Flux Pressure:
555 + 42 sin(20
x
pi
)
N/A/
Solid Core
Boundary
Mass Continuity
Condition:
∂ρ
∂t
+~∇·(~u (t) ρ) = 0
Continuity Condi-
tion:
∂ρ
∂t
+~∇·(~u (t) ρ) = 0
N/A/
Epidural
Layer
Boundary
Mass Flux = 0 Insulated Boundary N/A/
Injection
Needle Top
C = C inj, (Table 3) N/A/ Specified Inlet Ve-
locity = 2 m/s
Injection
Needle
Bottom
Continuity Condi-
tion:
∂ρ
∂t
+~∇·(~u (t) ρ) = 0
N/A/ Continuity Condi-
tion:
∂ρ
∂t
+~∇·(~u (t) ρ) = 0
Walls of the
Injection
Needle
Mass Flux = 0 N/A/ No-Slip Condition:
∂u×∂n = ∂U×∂n
, where ∂u is the
fluid velocity, ∂U is
the wall velocity, and
∂n is the unit vector.
Initial
Conditions
Initial Concentration
= 0 g/m3
Initial Pressure =
101325 atm
Initial Velocity = 0
m/s
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8 Appendix B: Input Parameters
The dimensions of the injection needle created by the catheter of the intrathecal pump was simulated to represent
dimensions of the apparatus created in studies evaluating the nature of CSF flow and the possibility of pulsatile delivery
of Baclofen (Hettiarachchi et al. (2011)).
The same held true for the clinical values for injection velocity for the drug delivery and input concentrations,
values that served as accuracy checks for optimum values attained in this simulation. As a continuous flow pump,
as modeled by the computational model used in this study, there are no additional engineering requirements on the
delivery route for Baclofen, and these dimensions were assumed to be clinically relevant. The dimensions of the
intrathecal space and the nerve root core, similarly, were attained from the pulsatile delivery study by Hettiarachchi
et al, using an average adult male spine as a measure for the physiological dimensions. Additional physiological
properties of the spine and CSF, along with diffusivity and pharmaceutical information about Baclofen were attained
from a variety of sources.
Table 2: Schematic Dimensions. The schematic can be referenced in Figure 3
Description Name Value Units
Radius of the
intrathecal space
(including the core)
r intra 0.01 m
Radius of the solid
core
r core 0.009 m
Height of observed
spine
h 0.1 m
Needle Radius r needle 0.0008 m
SA of the needle
injection point
SA needle 7.85398 · 10−7 m2
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Table 3: Input Parameters Pt. 1
Description Name Value Units
Pressure Boundary at
the Top
p top 101325 + 100 · sin(t) Pa
Pressure Boundary at
the Bottom
p bottom 101325− 100 · sin(t) Pa
Normal Inflow
Velocity of CSF
(Hettiarachchi et al.
(2011))
V in 0.002 · sin(x) m/s
Dynamic of
Viscosity of CSF
(Yetkin et al. (2010))
visc CSF 7.2 · 10−4 Pa ∗ s
Density of
CSF-filled space
(Hettiarachchi et al.
(2011))
d CSF 1000 kg ·m−3
Inlet Velocity of
Baclofen
(Hettiarachchi et al.
(2011))
V inj inj mass flow/C injSA of the needle injection point = 84.03 m/s
Diffusivity of
Baclofen
(Hettiarachchi et al.
(2011))
D bac 2.1 · 10−10 m2 · s−1
Molecular Weight of
Baclofen
(Hettiarachchi et al.
(2011))
MW bac 213.6 kg · kmol−1
Initial Concentration
of Baclofen
(Hettiarachchi et al.
(2011))
C inj 500 g ·m−3
20
Table 4: Input Parameters Pt. 2
Description Name Value Units
Permeability of
Baclofen in CSF (Lal
and Sukbuntherng
(2009)) (Deguchi
et al. (1995))
p bac CSF 8.82 · 10−11 m2
Permeability of
Baclofen in the solid
core (Lal and
Sukbuntherng
(2009)) (Deguchi
et al. (1995))
p bac core 2.58 · 10−13 m2
Porosity of spinal
cord (Hettiarachchi
et al. (2011))
p spinal 0.3 no units
Mean Viscous
Resistance of Spinal
Cord (Hettiarachchi
et al. (2011))
mvr spinal 1 · 1016 m−2
Infusion Duration
(Hettiarachchi et al.
(2011))
t infusion 30 s
Injection mass flow
(Hettiarachchi et al.
(2011))
inj mass flow 0.033 g · s−1
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9 Appendix C: Solution Strategy in COMSOL
9.1 Modules Used
Implementation of the mathematical statement of the problem was largely based on an example case found in COM-
SOL 4.2. The convection-diffusion equation was implemented using COMSOLs Diffusion and Convection Module
for Mass Species Transport. In the cases where Fluid Flow is concerned, either the Darcys Law Module, or the Navier-
Stokes Module for Incompressible Fluids was used. All of the subdomains implement the Diffusion and Convection
Module, the subdomains representing the spinal cord in this model all have fluid flow modeled by Darcys Law and the
needle subdomain is the only one that implements the Navier-Stokes Module.
9.2 Time Considerations: Transient and Time Stepping
9.2.1 Transient
Due to the nature of this problem, injection of drug into the body, a transient model would be most accurate and useful
representation of the situation. A transient model allow us to look critically at the time dimension of the problem and
study flow of drug over time (as opposed to steady state, in which the time dimension does not matter). In addition,
time data gathered would be useful in understanding the spread of the drug and what forces dominate in the movement
of the drug (see sensitivity analysis).
9.2.2 Time Stepping
Time steps Since there had been no reason to restrict the time-steps used by the solver in the solution process, the
default COMSOL algorithm was used to automatically choose whatever time-steps would work best for the problem.
9.3 Mesh
9.3.1 Design of Mesh
The basic design of the mesh was constructed using a default method COMSOL implements for free unstructured
M=meshes (Figure 12a).
Figure 12: Mesh Convergence
22
The advancing front option allows for finer and smaller elements around the injection site, the location where the
most and the largest of the changes in concentration were expected. Due to the fact that the mesh is unstructured and
implemented by COMSOL algorithms, the elements specified by the algorithm are tetrahedrals.
9.3.2 Mesh Convergence
The choice of mesh should not theoretically affect the solution but due to discretization errors, it is still an issue.
To make sure there is stability in the solution, regardless of the choice of mesh, the solution was calculated for a
variety of different meshes of varying number of elements. This was done using the built-in setting COMSOL has for
determining meshes. Meshes of 4 degrees of fineness were created to determine the the stability of the solution (In
Figure 12). In Figure 12, it is evident that there is a significantly more stable solution with element size larger than
40 000. At closer inspection of the solution, it was determined that there is a lot of variation in the advancing front
of the drug (Figure 13). The solution everywhere else in the solution is very stable. Since even in the finest mesh
analyzed, there still exists the instability, the decision was made to save processing time and power. The mesh with
20615 elements was used for all of the sensitivity analysis and accuracy checks(Figure 12b).
Figure 13: The 3D solution in COMSOL with labeled locations at which the average concentration of the solution
changes with the number of elements in the mesh.
There is a significant difference in the average concentration of the solution below 40 000 elements. This is likely
due to the instability of the convergence of the solution at the front of the spread of the drug as detailed in Figure 13.
9.4 Solver
To implement both the flow characteristics and the mass transport in COMSOL, an segregated iterative multigrid
solver was used. Due to the unique nature of the problem where there flow characteristics and mass transport are
coupled, a lot of computational power and memory needs to be used if the solution were to be determined all at once
in both governing equations. Therefore the solver used breaks this large solution down into smaller parts. The solver
first determines the flow patterns from the modules that determine velocity and pressure for the given time step. With
this data in hand, it solves for the concentration at each point of the solution for the same time step. Afterwards, this
repeats switching between solving for the flow and the mass transport until all of the timesteps have been taken. This
lightens the load for the amount of memory required to solve the problem.
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10 Appendix D: Additional Figures
(Please click to play video in Adobe Reader. The original video is in dropbox, under the folder: ”Final Paper.”)
Figure 14: The changing concentration profile over 60 seconds seen from a side view. This is also shown in Figure 7.
(Please click to play video in Adobe Reader. The original video is in dropbox, under the folder: ”Final Paper.”)
Figure 15: The changing concentration profile over 60 seconds seen from the top view.This is also shown in Figure 7.
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